oaDOI/unpaywall (OA fulltext)
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar
Merck LAPs Up Tilos for Its TGFβ-Targeting Tech
release_xabivb63xravxjhdwfocr4tl4e
Published
in Cancer Discovery
by American Association for Cancer Research (AACR).
2019 Volume 9, Issue 8, p989-990
Abstract
Merck will spend up to $773 million to acquire Tilos Therapeutics, a 3-year-old startup with a series of preclinical-stage antibodies that prevent the activation and release of TGFβ, a cytokine involved in thwarting the effectiveness of cancer immunotherapies.
In text/plain format
Archived Files and Locations
application/pdf
547.8 kB
file_htifqwupuragfizl6j3lttffqu
|
cancerdiscovery.aacrjournals.org (web) web.archive.org (webarchive) |
Read Archived PDF
Preserved and Accessible
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
access all versions, variants, and formats of this works (eg, pre-prints)
Lookup Links